US biotech Clovis Oncology (Nasdaq: CLVS) intends to submit a supplemental New Drug Application (sNDA) for rucaparib in a second-line or later maintenance treatment indication in ovarian cancer within four months.
The company made the announcement based on findings from the ARIEL3 study, the publication of which sent Clovis’ share price soaring on Monday morning by 45% in 90 minutes to $87.16.
"This is a very important step forward for women with advanced ovarian cancer"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze